SKYE — Skye Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $34.94m
- -$1.08m
Annual cashflow statement for Skye Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.56 | -8.52 | -19.5 | -37.6 | -26.6 |
| Depreciation | |||||
| Non-Cash Items | 0.411 | 1.37 | 7.38 | 24 | 3.66 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.094 | 0.647 | -0.762 | -0.469 | -2.63 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -6.05 | -6.47 | -12.7 | -14 | -25.2 |
| Capital Expenditures | -0.007 | -0.091 | -0.095 | -0.013 | -1.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | 5.31 | 6.61 | 1.36 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.007 | -0.091 | 5.21 | 6.6 | -0.246 |
| Financing Cash Flow Items | — | — | — | -0.006 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.7 | 13.1 | -0.209 | 16.4 | 83.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.639 | 6.51 | -7.74 | 9.09 | 58.1 |